Marc E. Lipmann, MD, MACP, FRCP: Chairman
Marc E. Lippman, is a professor in the departments of oncology and medicine at Georgetown University Medical Center. He formerly served as deputy director of Sylvester Comprehensive Cancer Center at the University of Miami, as well as the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Miller School of Medicine. He also served as Head of the Medical Breast Cancer Section of the National Cancer Institute. Throughout his career, Lippman has garnered many honors including a Clinical Investigator Award from the American Federation for Clinical Research, the Transatlantic Medal and Lecture from the British Endocrine Societies, the Astwood Award from the Endocrine Society, the Bernard Fisher Award from the University of Pittsburgh, the Rosenthal Award from the American Association for Cancer Research, and the Brinker Award for Basic Science from the Komen Foundation. Dr. Lippman has published over 500 peer-reviewed articles and is editor-in-chief of Breast Cancer Research and Treatment.
Robert Brooks, JD: CEO
See profile under Management
Robert Clarke, PhD: Co-Founder / Board Member
Robert Clarke, PhD, has served as Chief Executive Officer of Kinaset Therapeutics since 2020. He was previously Chief Executive Officer at Pulmatrix Inc. (NASDAQ:PULM), a clinical-stage respiratory drug delivery company, from 2012 to 2019 and successfully brought the company public in 2015. He joined Pulmatrix in 2004 as the first PhD-level scientist and was appointed Chief Scientific Officer in 2010. In that role he was focused on developing the Pulmatrix technologies for the treatment of respiratory diseases. During his tenure as Chief Executive Officer, Pulmatrix raised more than $50 million in public equity, $80 million in venture capital funding and more than $10 million in non-dilutive funding to support the company’s development programs. Prior to his tenure at Pulmatrix, Robert was Associate Director, Life Sciences at Alkermes. He holds Board seats at several institutions including EnBiotix, Johns Hopkins University and Boston University College of Engineering. Robert holds a PhD in physiology from Johns Hopkins University and completed his post-doctoral training in respiratory biology at Brigham and Women’s Hospital and Harvard University.